Hairy cell leukemia, an uncommon B-cell lymphoid neoplasia

Bouroncle, 1979, Leukemic reticuloendotheliosis (hairy cell leukemia), Blood, 53, 412, 10.1182/blood.V53.3.412.412 Schrek, 1966, “Hairy” cells in blood in lymphoreticular disease and “flagellated” cells of normal lymph nodes, Blood, 27, 199, 10.1182/blood.V27.2.199.199 Swerdlow, 2008 Clavel, 1995, Hairy cell leukaemia, occupation, and smoking, Br J Haematol, 91, 154, 10.1111/j.1365-2141.1995.tb05261.x Monnereau, 2014, Medical history, lifestyle, and occupational risk factors for hairy cell leukemia: the interlymph non-Hodgkin lymphoma subtypes project, J Natl Cancer Inst Monogr, 2014, 115, 10.1093/jncimonographs/lgu004 Oloske, 1985, A case control inquiry into the etiology of hairy cell leukemia, Am J Epidemiol, 121, 675, 10.1093/aje/121.5.675 Nordström, 1998, Occupational exposures, animal exposure and smoking as risk factors for hairy cell leukaemia evaluated in a case–control study, Br J Cancer, 77, 2048, 10.1038/bjc.1998.341 Staines, 1993, Hairy cell leukaemia: descriptive epidemiology and a case–control study, Br J Haematol, 85, 714, 10.1111/j.1365-2141.1993.tb03213.x Sopori, 2002, Effects of cigarette smoke on the immune system, Nat Rev Immunol, 2, 372, 10.1038/nri803 Oloris, 2010, Nicotine-mediated signals modulate cell death and survival of T lymphocytes, Toxicol Appl Pharmacol, 242, 299, 10.1016/j.taap.2009.10.020 Bernstein, 1990, Epidemiology of hairy cell leukemia in Los Angeles County, Cancer Res, 50, 3605 Ruiz-Arguelles, 1996, Hairy cell leukemia is infrequent in Mexico and has a geographic distribution, Am J Hematol, 318, 316, 10.1002/(SICI)1096-8652(199608)52:4<316::AID-AJH13>3.0.CO;2-B Pascual, 1994, Analysis of somatic mutation in five B cell subsets of human tonsil, J Exp Med, 180, 329, 10.1084/jem.180.1.329 Forconi, 2004, Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch, Blood, 104, 3312, 10.1182/blood-2004-03-0950 Arons, 2006, Somatic hypermutation and VH gene usage in hairy cell leukaemia, Br J Haematol, 133, 504, 10.1111/j.1365-2141.2006.06066.x Liu, 1996, Within germinal centers, isotype switching of immunoglobulin genes occurs after the onset of somatic mutation, Immunity, 4, 241, 10.1016/S1074-7613(00)80432-X Forconi, 2001, Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing, Blood, 98, 1174, 10.1182/blood.V98.4.1174 Arons, 2011, Evidence of canonical somatic hypermutation in hairy cell leukemia, Blood, 117, 4844, 10.1182/blood-2010-11-316737 Basso, 2004, Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors, J Exp Med, 199, 59, 10.1084/jem.20031175 Tiacci, 2006, Evolving concepts in the pathogenesis of hairy-cell leukaemia, Nat Rev Cancer, 6, 437, 10.1038/nrc1888 Forconi, 2005, Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies, Haematologica, 90, 266 Fecteau, 2006, A new memory CD27-IgG+ B cell population in peripheral blood expressing VH genes with low frequency of somatic mutation, J Immunol, 177, 3728, 10.4049/jimmunol.177.6.3728 Vanhentenrijk, 2004, Comparative expressed sequence hybridization studies of hairy cell leukemia show uniform expression profile and imprint of spleen signature, Blood, 104, 250, 10.1182/blood-2004-01-0181 Park, 1979 Miyoshi, 2001, Aberrant expression and localization of the cytoskeleton-binding pp52 (LSP1) protein in hairy cell leukemia, Leuk Res, 25, 57, 10.1016/S0145-2126(00)00079-5 Chung, 2014, Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia, Sci Transl Med, 6, 238ra71, 10.1126/scitranslmed.3008004 Tiacci, 2011, BRAF mutations in hairy-cell leukemia, N Engl J Med, 364, 2305, 10.1056/NEJMoa1014209 Tiacci, 2013, Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia, Haematologica, 98, 635, 10.3324/haematol.2012.078071 Hoffman, 2012, Hairy cell leukemia, 1192 Grever, 2010, How I treat hairy cell leukemia, Blood, 115, 21, 10.1182/blood-2009-06-195370 Jain, 2014, Update on the biology and treatment options for hairy cell leukemia, Curr Treat Options Oncol, 15, 187, 10.1007/s11864-014-0285-5 Zuzel, 2003, The biology of hairy cells, Best Pract Res Clin Haematol, 16, 1, 10.1016/S1521-6926(02)00082-8 Robak, 2015, Hairy cell leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 26, v100, 10.1093/annonc/mdv200 Uppal, 2015, The utility of BRAF V600e mutation-specific antibody VE1 for the diagnosis of hairy cell leukemia, Am J Clin Pathol, 143, 120, 10.1309/AJCPQLQ89VXTVWKN Cornet, 2014, Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia, Ann Hematol, 93, 1977, 10.1007/s00277-014-2140-y Jehn, 2004, An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine, Leukemia, 18, 1476, 10.1038/sj.leu.2403418 Maloisel, 2003, Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients, Leukemia, 17, 45, 10.1038/sj.leu.2402784 Grever, 2009, Long-term follow-up studies in hairy cell leukemia, Leuk Lymphoma, 50, 23, 10.3109/10428190903141820 Else, 2005, Long remissions in hairy cell leukemia with purine analogs, Cancer, 104, 2442, 10.1002/cncr.21447 Giblett, 1972, Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity, Lancet, 300, 1067, 10.1016/S0140-6736(72)92345-8 Cohen, 1978, Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency, Proc Natl Acad Sci U S A, 75, 472, 10.1073/pnas.75.1.472 Johnston, 2011, Mechanism of action of pentostatin and cladribine in hairy cell leukemia, Leuk Lymphoma, 52, 43, 10.3109/10428194.2011.570394 Rafel, 2000, Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients, Cancer, 88, 352, 10.1002/(SICI)1097-0142(20000115)88:2<352::AID-CNCR15>3.0.CO;2-8 Ribeiro, 1999, Long term outcome of patients with hairy cell leukemia treated with pentostatin, Cancer, 85, 65, 10.1002/(SICI)1097-0142(19990101)85:1<65::AID-CNCR9>3.0.CO;2-B Flinn, 2000, Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin, Blood, 96, 2981 Grever, 2003, Pentostatin in the treatment of hairy-cell leukemia, Best Pract Res Clin Haematol, 16, 91, 10.1016/S1521-6926(03)00002-1 Steis, 1991, Kinetics of recovery of CD4+ T cells in peripheral blood of deoxycoformycin-treated patients, J Natl Cancer Inst, 83, 1678, 10.1093/jnci/83.22.1678 Urba, 1989, Deoxycoformycin-induced immunosuppression with hairy cell leukemia, Blood, 73, 38 Robak, 1999, 2-Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland, Eur J Haematol, 62, 49, 10.1111/j.1600-0609.1999.tb01114.x Rosenberg, 2014, Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series, Blood, 123, 177, 10.1182/blood-2013-06-508754 Goodman, 2003, Extended follow-up of patients with hairy cell leukemia after treatment with cladribine, J Clin Oncol, 21, 891, 10.1200/JCO.2003.05.093 Chadha, 2005, Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience, Blood, 106, 241, 10.1182/blood-2005-01-0173 Robak, 1996, 2-Chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia, Leuk Lymphoma, 22, 107, 10.3109/10428199609051736 Robak, 2007, Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial, Blood, 109, 3672, 10.1182/blood-2006-08-042929 Lauria, 1999, Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications, Haematologica, 84, 22 von Rohr, 2002, Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study, Ann Oncol, 13, 1641, 10.1093/annonc/mdf272 Zenhäusern, 2009, Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98), Leuk Lymphoma, 50, 1501, 10.1080/10428190903131755 Nieva, 2003, Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia, Blood, 102, 810, 10.1182/blood-2003-01-0014 Thomas, 2003, Rituximab in relapsed or refractory hairy cell leukemia, Leukemia, 102, 3906 Else, 2011, Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence, Leuk Lymphoma, 52, 75, 10.3109/10428194.2011.568650 Ravandi, 2011, Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia, Blood, 118, 3818, 10.1182/blood-2011-04-351502 Ravandi, 2006, Eradication of minimal residual disease in hairy cell leukemia, Blood, 107, 4658, 10.1182/blood-2005-11-4590 Tiacci, 2015, Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia, N Engl J Med, 373, 10.1056/NEJMoa1506583 Sivina, 2014, The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach, Br J Haematol, 166, 177, 10.1111/bjh.12867 Jain, 2015, Novel therapeutic options for relapsed hairy cell leukemia, Leuk Lymphoma, 1 Kreitman, 2009, Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia, J Clin Oncol, 27, 2983, 10.1200/JCO.2008.20.2630 Kreitman, 2012, Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia, J Clin Oncol, 30, 1822, 10.1200/JCO.2011.38.1756 Ruiz-Delgado, 2012, Treatment of hairy cell leukemia: long-term results in a developing country, Hematology, 17, 140, 10.1179/102453312X13376952196331 Gómez Almaguer, 1998, Interferón alfa intermitente en el tratamiento de la LCP, Rev Invest Clin, 50, 331 Jansen, 1981, Splenectomy in hairy cell leukemia: a retrospective muliticenter analysis, Cancer, 47, 2066, 10.1002/1097-0142(19810415)47:8<2066::AID-CNCR2820470827>3.0.CO;2-V Van Norman, 1986, Splenectomy for hairy cell leukemia. A clinical review of 63 patients, Cancer, 57, 644, 10.1002/1097-0142(19860201)57:3<644::AID-CNCR2820570341>3.0.CO;2-O Lad, 2014, Outcomes of splenectomy versus cladribine in resource limited settings in hairy cell leukemia, Leuk Lymphoma, 55, 1428, 10.3109/10428194.2013.839786 Sarvaria, 2015, Current therapy and new directions in the treatment of hairy cell leukemia a review, JAMA Oncol, 2, 123, 10.1001/jamaoncol.2015.4134 Lopez-Rubio, 2015, Current and emerging treatment options for hairy cell leukemia, Onco Targets Ther, 8, 2147, 10.2147/OTT.S70316 Poret, 2015, CD38 in hairy cell leukemia is a marker of poor prognosis and a new target for therapy, Cancer Res, 75, 3902, 10.1158/0008-5472.CAN-15-0893